Market Overview

Motus GI Strengthens IP Portfolio with Issuance of Japanese Patent for the Pure-Vu® System


Expansion of global IP portfolio continues to lay foundation for
future growth opportunities in key markets outside the United States

GI Holdings, Inc.
, (NASDAQ:MOTS) ("Motus GI" or the "Company"), a
medical technology company dedicated to improving endoscopy outcomes and
experiences, announced today that the Japanese Patent Office has issued
a patent covering claims related to the Company's flagship product, the Pure-Vu®
, a medical device that cleanses the colon intra-procedurally
to facilitate improved visualization during a colonoscopy procedure to
enable a quality exam and has demonstrated effective cleaning in
hundreds of procedures.

"The need to improve the quality, efficiency and cost-effectiveness of
inpatient colonoscopy procedures is a global issue. While our immediate
focus continues to be on market development and preparation for
commercial launch of the Pure-Vu® System for inpatient colonoscopy in
the U.S., we believe Japan is a key international market for future
commercial expansion," commented Mark
Pomeranz, CEO of Motus GI
. "Our goal is to make the Pure-Vu® System
the standard of care for inpatient colonoscopy procedures worldwide, and
we are pleased to see our global IP portfolio continue to expand

Motus GI is currently focused on post-approval clinical trials and pilot
commercial evaluations of the Pure-Vu® System with leading U.S.
hospitals in preparation for a commercial launch in the U.S. and select
international markets in 2019 focused on the inpatient, hospital-based
colonoscopy market where challenges with bowel prep slow diagnosis,
diminish the quality of care, and add significant costs for hospitals.
Challenges with bowel preparation for inpatient colonoscopy represent a
significant area of unmet need that directly affects clinical outcomes
and the cost of care in a market that comprises nearly 4 million annual
procedures worldwide. Published studies have found that the inpatient
population has high rates of insufficiently prepped colons, which can
lead to significantly longer hospital stays and other additional costs.
This is exemplified in a recently published study from Northwestern
University Hospital System which showed an average hospital stay
extension of two days and cost increase of as much as $8,000 per patient
as a result of challenges associated with bowel preparation. Motus GI
believes that the Pure-Vu® System may potentially reduce healthcare
costs by reliably and predictably moving patients through the hospital
system to a successful examination.

About the Pure-Vu® System

The Pure-Vu® System is a 510(k) U.S. Food and Drug Administration
cleared medical device indicated to help facilitate the cleaning of a
poorly prepared colon during the colonoscopy procedure. The device
integrates with standard colonoscopes to enable cleaning during the
procedure while preserving standard procedural workflow and techniques.
The Pure-Vu® System has received CE mark approval in Europe. The
Pure-Vu® System is currently being introduced on a pilot basis in the
U.S. market, and the Company is planning to initiate a full commercial
launch focused on the inpatient colonoscopy market in the U.S. and
select international markets in 2019.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving endoscopy
outcomes, lowering costs and enhancing patient experiences. The Company
is focused on the development and commercialization of the Pure-Vu®
System to improve the colonoscopy experience and assist in the early
detection and prevention of colorectal cancer and other diseases of the
rectum and colon. In clinical studies to date, the Pure-Vu® System
significantly increased the number of patients with an adequate
cleansing level, according to the Boston Bowel Preparation Scale Score,
a validated assessment instrument.

For more information, visit
and connect with the Company on Twitter,
and Google+.

Forward-Looking Statements

This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, "expect," "anticipate," "intend," "plan,"
"believe," "estimate," "potential," "predict," "project," "should,"
"would" and similar expressions and the negatives of those terms.
Prospective investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this
presentation. The Company undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new information,
future events or otherwise. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements are set forth in the Company's filings with the Securities
and Exchange Commission.

View Comments and Join the Discussion!